Sfaf 2013

Genohub · 05-30-2013, 12:56 PM

Day 1 highlights of Sequencing, Finishing and Analysis in the Future Meeting (SFAF 2013)

• All four platforms are actively trying to increase their read lengths (although we didn’t see significant guidance beyond Ion’s 400 bp reads)
• Haley mentioned that Illumina’s latest aquisition of Moleculo technology might one day replace current Mate-pair library prep (if prices can be lowered).
• MiSeq DX was pulled back because Illumina has been able to increase MiSeq output. A clinical instrument will require a locked down platform.
• Turner said that he expects 30,000 PacBio base pairs in 3 years. Shearing technologies and polymerases would have to be improved for better-read lengths.
• PGM can produce >2G aligned Q20 bases with even coverage (E. coli) using their 318, 400 bp chip.
• Fiske said that Illumina spends 25% of revenue on R&D, Life Tech and Thermo spend 5% and 3% respectively.
• Illumina needs help with better and higher fidelity polymerases. Suggested that Illumina would consider purchasing companies who have breakthrough technologies related to polymerases.

SFAF day 1 summary

Similar Threads
Thread	Thread Starter	Forum	Replies	Last Post
AGBT 2013 posters	swarner	Events / Conferences	0	02-26-2013 11:09 AM
Agbt 2013	paulk	Events / Conferences	0	02-16-2013 08:01 AM
'Spring School 2013 - Epigenetics of Civilization Diseases', May 27th - 31st 2013	ecSeq Bioinformatics	Events / Conferences	1	01-31-2013 02:17 PM
Have a great 2013!	EricP	Introductions	0	01-09-2013 03:03 AM

05-30-2013, 12:56 PM	#1
Genohub Registered Vendor Location: genohub.com Join Date: Mar 2013 Posts: 210	Sfaf 2013 Day 1 highlights of Sequencing, Finishing and Analysis in the Future Meeting (SFAF 2013) • All four platforms are actively trying to increase their read lengths (although we didn’t see significant guidance beyond Ion’s 400 bp reads) • Haley mentioned that Illumina’s latest aquisition of Moleculo technology might one day replace current Mate-pair library prep (if prices can be lowered). • MiSeq DX was pulled back because Illumina has been able to increase MiSeq output. A clinical instrument will require a locked down platform. • Turner said that he expects 30,000 PacBio base pairs in 3 years. Shearing technologies and polymerases would have to be improved for better-read lengths. • PGM can produce >2G aligned Q20 bases with even coverage (E. coli) using their 318, 400 bp chip. • Fiske said that Illumina spends 25% of revenue on R&D, Life Tech and Thermo spend 5% and 3% respectively. • Illumina needs help with better and higher fidelity polymerases. Suggested that Illumina would consider purchasing companies who have breakthrough technologies related to polymerases. SFAF day 1 summary Last edited by Genohub; 07-29-2013 at 03:16 PM. Reason: link update